Evaluate Buys Black Swan Analysis

Pharma sector commercial intelligence and predictive analytics provider Evaluate has acquired UK-based Black Swan Analysis, which provides valuations, commercialisation plans and insight for companies in the healthcare industry. Terms of the deal have not been disclosed.

Founded in 2007, Black Swan focuses on bespoke epidemiology and segmentation, with additional competencies including asset valuation, modelling and market forecasting, along with portfolio and lifecycle optimisation. Clients can use the firm's product development and lifestyle database to explore the journey of a healthcare product through R&D, regulatory approval, launch of additional indications, to loss of exclusivity. Key products include clinical trial and portfolio optimisation tool 'The Journey', which offers an understanding of products' route to market; the 'Epiomic Database', an online, evidence-based source for patient populations in over 230 disease areas across 27 countries; and RxPriceIndex, which delivers insights and up-to-date pharmaceutical pricing data across the European, American and Japanese markets.

Evaluate, which has been a partner of Black Swan for many years, says the acquisition directly aligns with its core strategy of providing valuations of pharmaceutical assets. Black Swan CEO Nic Talbot-Watt (pictured) comments: 'Evaluate is known as a key leader in providing innovative data solutions to the pharmaceutical industry. It's fantastic to be a part of an organisation with a track record of success and an exciting growth trajectory. Our mantra has always been to bring valuable insight and high-quality solutions to our clients, and I know that fully aligns with Evaluate's strategy'.

Web sites: www.evaluate.com and www.blackswan-analysis.co.uk .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.